Scarica l'app Stockscreener
23.80
18.94%
3.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.01
Aprire:
$20.24
Volume 24 ore:
1.88M
Relative Volume:
1.83
Capitalizzazione di mercato:
$1.58B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-9.2248
EPS:
-2.58
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
+7.55%
1M Prestazione:
+3.88%
6M Prestazione:
+6.92%
1 anno Prestazione:
-28.87%
Intervallo 1D:
$20.19
$23.88
Intervallo di 1 settimana:
$19.72
$23.88
Portata 52W:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
23.80 | 1.33B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Can Celldex Therapeutics Inc. hit a new high this monthFree Weekly Top Gainers Forecast Watchlist - Newser
Celldex Therapeutics Inc.’s volatility index tracking explainedFree Early Entry Picks Before News Breakout - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsLow Risk Stock Trade Opportunity Analysis - Newser
Will Celldex Therapeutics Inc. price bounce be sustainablePortfolio Risk Distribution Analysis Tool - Newser
Building trade automation scripts for Celldex Therapeutics Inc.Stock Forecast Tools for Retail Traders - Newser
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.Equity Forecast with Predictive AI Screener - Newser
Is Celldex Therapeutics Inc. stock a good hedge against inflationInstitutional Holding Behavior Pattern Analysis - Newser
How Celldex Therapeutics Inc. stock performs during market volatilityChart-Based Entry Confirmation for Beginners - Newser
Using portfolio simulators with Celldex Therapeutics Inc. includedFree Daily Picks With Predictable Performance - Newser
Can volume confirm reversal in Celldex Therapeutics Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Trend analysis for Celldex Therapeutics Inc. this weekPrice Movement and Market Sentiment Analysis - Newser
Will Celldex Therapeutics Inc. continue its uptrendTrading Volume Spike and Reversal Analysis - Newser
Published on: 2025-08-10 21:08:39 - Newser
Buy Signal for Celldex Therapeutics Inc. Stock Key Technical Indicators to WatchFree AI Driven Buy Alert Trade Blueprint - Newser
Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Celldex Therapeutics Q2 2025 Earnings Miss Estimates, Revenue Falls Short at $0.7 Million - AInvest
Celldex's Strong Financial Position and Promising Pipeline Support Buy Rating Despite Risks - AInvest
Celldex Therapeutics 2025 Q2 Earnings Dramatic Loss Widening - AInvest
Celldex reports Q2 EPS (85c), consensus (84c) - TipRanks
Celldex Therapeutics: Navigating Short-Term Losses to Unlock Long-Term Value in a High-Stakes Biotech Play - AInvest
Celldex: Q2 Earnings Snapshot - San Antonio Express-News
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $700,000 vs. FactSet Est of $1.0M - MarketScreener
Celldex Therapeutics Inc. Charts Flash Early Recovery SignalsLong Hold Safe Return Strategy Reviewed - metal.it
What makes Celldex Therapeutics Inc. stock price move sharplyHigh-yield market plays - Jammu Links News
What drives Celldex Therapeutics Inc. stock priceSuperior return velocity - Jammu Links News
How does Celldex Therapeutics Inc. generate profit in a changing economyExponential return rates - Jammu Links News
Is it the right time to buy Celldex Therapeutics Inc. stockDynamic investment growth - Jammu Links News
What analysts say about Celldex Therapeutics Inc. stockOutstanding capital appreciation - Jammu Links News
What is the dividend policy of Celldex Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is the risk reward ratio of investing in Celldex Therapeutics Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
Should I hold or sell Celldex Therapeutics Inc. stock in 2025Capitalize on strategic market trends - Jammu Links News
Why is Celldex Therapeutics Inc. stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Is Celldex Therapeutics Inc. a good long term investmentTrack high-yield stocks before they peak - Jammu Links News
What are analysts’ price targets for Celldex Therapeutics Inc. in the next 12 monthsUnlock powerful trading signals for profits - Jammu Links News
Does Celldex Therapeutics Inc. stock perform well during market downturnsInvest in stocks with strong fundamentals - Jammu Links News
Celldex Therapeutics Inc. Stock Analysis and ForecastCapitalize on emerging market sectors - Jammu Links News
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):